Incyte’s Earnings: Strong Growth Amid Market Overlook

Incyte Corporation (INCY): When 93% Gross Margins Meet Zero Debt, the Market Still Isn’t Paying Attention Most biotech investors chase the next FDA approval like lottery tickets, hoping lightning strikes before the cash burns out. Incyte plays a different game entirely. This is a company generating $1.17 billion in annual free cash flow, carrying zero meaningful debt, and sitting on $3.6 billion in cash, yet the stock trades at roughly 15.6x trailing earnings after a post-earnings pullback. That is not how the market usually prices a profitable biotech with multiple commercialized drugs and a broadening pipeline. Something is mispriced, and the setup favors patient buyers willing to look past the headline noise around Jakafi’s patent window. The Business Behind the Numbers Incyte is not a one-drug story, though it started as one. Jakafi (ruxolitinib), a first-in-class JAK1/JAK2 inhibitor approved in 2011 for myelofibrosis, became the company’s foundation. In 2025, Jakafi generated $3.093 billion in revenue across its approved indications: myelofibrosis, polycythemia vera, steroid-refractory acute graft-versus-host disease, and chronic GVHD. Think of Jakafi as the toll bridge over a river with no competing crossings, a monopoly asset throwing off enormous cash flow for over a decade. And there is still headroom: PV penetration sits at only 30% versus 60-70% in frontline MF, which management highlighted on this morning’s earnings call. But Incyte has been quietly building a second bridge while everyone fixates on the first one’s expiration date. Opzelura (topical ruxolitinib cream), the company’s dermatology franchise, delivered $678 million in 2025 revenue with 33% year-over-year growth, and management guided $750-790 million for 2026 including a late-year European launch in moderate atopic dermatitis. It treats atopic dermatitis and vitiligo, with pediatric atopic dermatitis expansion and hidradenitis suppurativa trials underway. Then add Niktimvo (axatilimab) for chronic GVHD, which generated $152 million in its first year on the market. Monjuvi (tafasitamab) reported positive topline results as a first-line treatment for diffuse large B-cell lymphoma in January 2026 and is on track for a supplemental BLA submission in the first half of 2026, potentially transforming it from a niche product into a three-indication standard-of-care anchor by early 2027. And Zynyz (retifanlimab) received a positive CHMP opinion for first-line advanced anal cancer in Europe. This is not a company desperately searching for its next act. This is a company methodically building overlapping revenue streams while the cash engine runs full throttle. The Q4 2025 results released this morning confirmed the trajectory: total revenue hit $1.51 billion (up 28% YoY), smashing the $1.35 billion consensus by 11.4%. Full year 2025 net product sales of $4.35 billion exceeded the high end of $4.23-4.32 billion guidance. The core business excluding Jakafi reached $1.26 billion, up 53% year-over-year, a number that would have seemed aspirational just two years ago. The one blemish: adjusted EPS of $1.80 missed the $1.91 consensus by about 6%, driven by heavier R&D spending ($611 million in Q4 alone, up 31%) as the company invests aggressively in its late-stage pipeline. That R&D ramp is what’s funding 14 pivotal trials and four anticipated product launches between late 2026 and early 2027. Investors sold the EPS miss this morning, pushing shares from $108 to $100. For systematic buyers, that is a gift. The broader pipeline adds optionality the market is largely ignoring. Povorcitinib, a JAK1-specific inhibitor, has its NDA submitted for hidradenitis suppurativa with European filing also completed, targeting approval in late 2026. If approved, it could become a major franchise in a disease affecting roughly 1% of the global population with limited treatment options, and management called it a potential multibillion-dollar product. The CDK2 inhibitor